LLY

791.36

-1.92%↓

JNJ

152.37

-1.77%↓

ABBV

185.23

-2.89%↓

NVO

74.38

-3.34%↓

UNH

308.61

+0.35%↑

LLY

791.36

-1.92%↓

JNJ

152.37

-1.77%↓

ABBV

185.23

-2.89%↓

NVO

74.38

-3.34%↓

UNH

308.61

+0.35%↑

LLY

791.36

-1.92%↓

JNJ

152.37

-1.77%↓

ABBV

185.23

-2.89%↓

NVO

74.38

-3.34%↓

UNH

308.61

+0.35%↑

LLY

791.36

-1.92%↓

JNJ

152.37

-1.77%↓

ABBV

185.23

-2.89%↓

NVO

74.38

-3.34%↓

UNH

308.61

+0.35%↑

LLY

791.36

-1.92%↓

JNJ

152.37

-1.77%↓

ABBV

185.23

-2.89%↓

NVO

74.38

-3.34%↓

UNH

308.61

+0.35%↑

Search

Apellis Pharmaceuticals Inc

Closed

SectorHealthcare

17.78 -2.95

Overview

Share price change

24h

Current

Min

17.66

Max

18.31

Key metrics

By Trading Economics

Income

-56M

-92M

Sales

-46M

167M

EPS

-0.74

Profit margin

-55.292

Employees

705

EBITDA

-56M

-80M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+101.26% upside

Dividends

By Dow Jones

Next Earnings

31 lip 2025

Market Stats

By TradingEconomics

Market Cap

-190M

2.4B

Previous open

20.73

Previous close

17.78

Apellis Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

17 cze 2025, 14:44 UTC

Acquisitions, Mergers, Takeovers

Justice Department Orders Safran to Sell Assets to Proceed with Buy of Collins Aerospace Business

17 cze 2025, 23:43 UTC

Market Talk

Nikkei May Fall Amid Uncertainty Over Israel-Iran Conflict -- Market Talk

17 cze 2025, 23:34 UTC

Market Talk

Gold Steady, Underpinned by Ongoing Geopolitical Tensions -- Market Talk

17 cze 2025, 23:22 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 cze 2025, 23:22 UTC

Market Talk

Global Energy Roundup: Market Talk

17 cze 2025, 23:22 UTC

Market Talk

Meridian Energy Set to Draw Line Under 'Annus Horribilis' -- Market Talk

17 cze 2025, 23:17 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Tourism Holdings Likely to Seek Higher Offer -- Market Talk

17 cze 2025, 23:05 UTC

Market Talk

Fletcher Building Could Signal Improved Shareholder Returns -- Market Talk

17 cze 2025, 23:05 UTC

Market Talk

Global Equities Roundup: Market Talk

17 cze 2025, 22:58 UTC

Market Talk

Australian Treasurer Chalmers Expected to Outline Second-Term Reform Agenda -- Market Talk

17 cze 2025, 22:55 UTC

Market Talk
Acquisitions, Mergers, Takeovers

XRG Has a Good Argument for Regulatory Approval of Santos Deal -- Market Talk

17 cze 2025, 22:31 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Lifeway Foods CEO Not Surprised by Takeover Interest -- Market Talk

17 cze 2025, 22:14 UTC

Major Market Movers

Bitdeer Technologies Group Shares Fall on Note Offering

17 cze 2025, 19:49 UTC

Market Talk

Natural Gas Slow Down Gains -- Market Talk

17 cze 2025, 19:34 UTC

Market Talk

Oil Rises On Israel-Iran Conflict Uncertainty -- Market Talk

17 cze 2025, 19:10 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 cze 2025, 19:10 UTC

Market Talk

Dollar Strengthens, Treasury Yields Fall in Risk-Off Trade -- Market Talk

17 cze 2025, 18:41 UTC

Market Talk

Slowdown in US Consumer Spending Expected -- Market Talk

17 cze 2025, 18:15 UTC

Market Talk

Gold Inches Down as Profit-Taking Seen -- Market Talk

17 cze 2025, 17:44 UTC

Market Talk

Analysts Forecast Record-High Ethanol Output -- Market Talk

17 cze 2025, 16:37 UTC

Market Talk

A Buy-Canadian Policy Could Support Steel Producers -- Market Talk

17 cze 2025, 16:30 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

17 cze 2025, 16:30 UTC

Market Talk

Canada Seen Likely to Drop Digital-Services Tax -- Market Talk

17 cze 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

17 cze 2025, 16:15 UTC

Market Talk

Base Metal Prices Mixed on Risk-Off Sentiment -- Market Talk

17 cze 2025, 16:12 UTC

Market Talk

Gold Futures Fall as Safe-haven Demand Retreats -- Market Talk

17 cze 2025, 14:54 UTC

Market Talk

Oil Rises on Continued Israel-Iran Conflict -- Market Talk

17 cze 2025, 14:47 UTC

Market Talk

European Gas Climbs on Middle East Risks, EU Russian Ban Proposal -- Market Talk

17 cze 2025, 14:41 UTC

Market Talk

Natural Gas Extends Climb -- Market Talk

17 cze 2025, 14:40 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

Peer Comparison

Price change

Apellis Pharmaceuticals Inc Forecast

Price Target

By TipRanks

101.26% upside

12 Months Forecast

Average 36.83 USD  101.26%

High 60 USD

Low 18 USD

Based on 20 Wall Street analysts offering 12 month price targets forApellis Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

20 ratings

12

Buy

8

Hold

0

Sell

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.